

## Product datasheet for **TL312228**

### IFRD1 Human shRNA Plasmid Kit (Locus ID 3475)

#### Product data:

Product Type:	shRNA Plasmids
Product Name:	IFRD1 Human shRNA Plasmid Kit (Locus ID 3475)
Locus ID:	3475
Synonyms:	PC4; TIS7
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	IFRD1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 3475). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	<a href="#">NM_001007245</a> , <a href="#">NM_001197079</a> , <a href="#">NM_001197080</a> , <a href="#">NM_001550</a> , <a href="#">NR_120333</a> , <a href="#">NM_001007245.1</a> , <a href="#">NM_001007245.2</a> , <a href="#">NM_001550.1</a> , <a href="#">NM_001550.2</a> , <a href="#">NM_001550.3</a> , <a href="#">NM_001197079.1</a> , <a href="#">NM_001197080.1</a> , <a href="#">BC001272</a> , <a href="#">BC001272.1</a>
UniProt ID:	<a href="#">O00458</a>
Summary:	This gene is an immediate early gene that encodes a protein related to interferon-gamma. This protein may function as a transcriptional co-activator/repressor that controls the growth and differentiation of specific cell types during embryonic development and tissue regeneration. Mutations in this gene are associated with sensory/motor neuropathy with ataxia. This gene may also be involved in modulating the pathogenesis of cystic fibrosis lung disease. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).